ArticleiScience2026

A phase 3 trial of GB-K02 pegfilgrastim biosimilar for preventing chemotherapy-induced neutropenia in breast cancer.

Jinhai Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.